Pinpoint Asset Management Singapore Pte. Ltd. purchased a new stake in shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 340,497 shares of the company's stock, valued at approximately $4,760,000. Dr. Reddy's Laboratories comprises approximately 0.9% of Pinpoint Asset Management Singapore Pte. Ltd.'s holdings, making the stock its 19th largest position.
A number of other large investors have also added to or reduced their stakes in RDY. JPMorgan Chase & Co. grew its holdings in shares of Dr. Reddy's Laboratories by 157.7% in the second quarter. JPMorgan Chase & Co. now owns 5,910,786 shares of the company's stock valued at $88,839,000 after purchasing an additional 3,617,435 shares in the last quarter. Aikya Investment Management Ltd increased its position in Dr. Reddy's Laboratories by 5.7% in the third quarter. Aikya Investment Management Ltd now owns 6,715,007 shares of the company's stock worth $93,876,000 after purchasing an additional 360,028 shares during the last quarter. Bessemer Group Inc. raised its stake in Dr. Reddy's Laboratories by 30.9% during the third quarter. Bessemer Group Inc. now owns 1,350,988 shares of the company's stock valued at $18,887,000 after purchasing an additional 318,621 shares in the last quarter. Vanguard Group Inc. raised its stake in Dr. Reddy's Laboratories by 3.0% during the third quarter. Vanguard Group Inc. now owns 5,123,709 shares of the company's stock valued at $71,629,000 after purchasing an additional 148,662 shares in the last quarter. Finally, Vise Technologies Inc. bought a new position in Dr. Reddy's Laboratories during the second quarter valued at $285,000. Institutional investors own 3.85% of the company's stock.
Dr. Reddy's Laboratories Trading Up 0.8%
Shares of RDY stock opened at $14.39 on Monday. The company has a market cap of $12.01 billion, a PE ratio of 18.69, a price-to-earnings-growth ratio of 13.08 and a beta of 0.34. Dr. Reddy's Laboratories Ltd has a 1 year low of $12.26 and a 1 year high of $16.17. The stock's 50 day simple moving average is $13.90 and its two-hundred day simple moving average is $14.06. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.88 and a quick ratio of 1.38.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its earnings results on Wednesday, January 21st. The company reported $0.16 EPS for the quarter, hitting analysts' consensus estimates of $0.16. The firm had revenue of $969.81 million during the quarter, compared to analysts' expectations of $963.84 million. Dr. Reddy's Laboratories had a return on equity of 15.89% and a net margin of 16.41%. Research analysts predict that Dr. Reddy's Laboratories Ltd will post 0.8 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings cut shares of Dr. Reddy's Laboratories from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Friday, February 13th. One research analyst has rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $16.90.
View Our Latest Research Report on Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Profile
(
Free Report)
Dr. Reddy's Laboratories Ltd. is an India‐based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.
The company's core activities include the development and commercialization of cost‐effective generic treatments for branded drugs that have lost patent protection, along with in‐house research into innovative molecule development.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
